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ABSTRACT
Introduction: Infection with vancomycin-resistant Enterococcus spp (VRE) has been 
a worldwide problem since mid 1980’s and, in Brazil, since 1996. This study was 
conducted to evaluate the experience with VRE in our institution.
Methods: A prospective cohort study from 2000 to 2009 was conducted at Hospital 
São Lucas da PUCRS. All hospitalized patients with VRE positive culture were included 
and followed from their diagnosis until they were negative for VRE or their discharge. 
Only the first admission for each VRE positive patient was included. Pulsed field gel 
electrophoresis (PFGE) was performed to determine how VRE had spread.
Results: A total of 315 cases of VRE were identified, 224 of which were isolated from 
rectal swabs. Vancomycin-resistant/ampicilin susceptible Enterococcus faecalis were 
identified in 312 isolates. PFGE was performed in 47 VRE isolates that presented an 
indistinguishable migratory profile. The median length of hospital stay and length of 
stay before VRE isolation were 46 days and 21 days, respectively; 52% of the patients 
were aged 60 and above. The annual distribution of the new VRE cases showed a 
clear decrease from 2000 to 2009.
Discussion: This study shows a substantial VRE colonization (71%) with a homogenous 
pattern that emphasizes its transversal spread. Predominance of E. faecalis differs 
from the literature which largely describes a higher prevalence of vancomycin-resistant 
Enterococcus faecium. The follow up of VRE during 9 years in our institution highlighted 
the importance of continuous surveillance to prevent outbreaks in our hospital.
Keywords: Vancomycin-resistant Enterococcus, VRE, outbreak, surveillance.
Enterococci are normal inhabitants of the intestinal tract of humans and 
animals1. Their capacity to colonize the host for long periods of time, to 
survive in inanimate objects, and to be resistant to many commonly used 
antibiotics ensures their success as a nosocomial pathogen1-5. Enterococcus 
spp can cause serious infections such as bacteremia, urinary tract infection, 
endocarditis, and intra-abdominal infection, mainly in immunocompromised 
patients5. Among the Enterococcus species, Enterococcus faecalis and 
E. faecium are the most common, corresponding to 80-90% and 5-10% of 
clinical isolates, respectively1,5. This proportion has shifted somewhat as 
E. faecium has become increasingly resistant to antimicrobial agents and 
emerged as a major nosocomial pathogen6,7.
Infection with vancomycin-resistant Enterococcus (VRE) has been an 
increasing problem worldwide since the first reports in France and the United 
Kingdom in 19888,9. VRE had spread rapidly throughout the world, particularly 
in the United States where 30% of the enterococci isolated from intensive 
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care units (ICUs) are resistant to vancomycin10-12. In 
Europe, infections caused by VRE are also a problem 
and correspond to 7% of the enterococcal isolates 
from blood culture; VRE are also important in the 
community and there is a relatively large reservoir 
of VRE that had been linked to the use of avoparcin 
in livestock13-15. In Brazil, the first case of VRE was 
reported in 1996, in Curitiba, and new cases were 
reported in the following year in the city of São Paulo 
and other cities16,17.
There are many risk factors for acquiring VRE: 
previous use of antibiotics, prolonged hospitalization, 
long ICU stay, immunossupression, and abdominal 
or thoracic surgery18,19. The spread of VRE in hospital 
settings has been widely reported and are usually 
due to: 1) patient-to-patient transmission, 2) hand 
contact of healthcare workers, or 3) contaminated 
environmental surfaces and medical equipment20-24.
The aim of the present study was to evaluate our 
local experience with VRE in Hospital São Lucas da 
Pontifícia Universidade Católica do Rio Grande do 
Sul (HSL/PUCRS), located in southern Brazil.
METHODS
Patients and Setting
The study was conducted at HSL/PUCRS, a 
600-bed tertiary care teaching institution located in 
the city of Porto Alegre, southern Brazil. The study 
population consisted of hospitalized patients with 
clinical or surveillance cultures positive for VRE. The 
study period was from May 2000, when VRE was 
isolated for the first time in our General Intensive 
Care Unit (GICU), through May 2009. Only one 
hospitalization per patient was considered. Outpatients 
were not included.
Study Design
We conducted a prospective cohort study including 
all hospitalized patients colonized and/or infected 
with VRE, who were followed up from the date of 
their diagnosis to the date they were negative for 
VRE or to their discharge from the hospital.
Bacterial Culture and Identification
Enterococci were obtained from clinical specimens 
or from rectal swabs during surveillance culture. 
Surveillance culture was performed once a week in 
patients admitted to the GICU, and at any time in 
patients who had shared a room with a VRE positive 
patient for more than 48 hours, according to the 
recommendations of the Infection Control Service 
(ICS) of our hospital.
The culture and identification of Enterococcus 
spp was performed according to conventional tests. 
The susceptibility of enterococci to vancomycin 
was evaluated using the disk diffusion method and 
followed the Clinical and Laboratory Standards 
Institute25. Results for isolates classified as resistant 
to vancomycin by the disk diffusion method were 
confirmed by the E-test method.
Molecular Typing
To determine how VRE had been spread, the 
genotypic profile of VRE isolates obtained from clinical 
specimens and rectal swabs was determined at the 
Biomedical Research Unit of the Clinical Pathology 
Service at Hospital de Clínicas de Porto Alegre 
(HCPA). Molecular typing was performed by DNA 
macrorestriction followed by pulsed field electrophoresis 
(PFGE) as previously described26. Briefly, unshared 
DNA was extracted from the bacterial culture and 
digested with Sma1 for 20 hours in a 30ºC water bath. 
After digestion, the DNA fragments were subjected 
to PFGE in a CHEF-DR® II apparatus (Bio-Rad 
Laboratories, California, USA). In order to evaluate 
the discriminatory power of PFGE, vancomycin-
susceptible Enterococcus spp (VSE) obtained from 
the same patients were also evaluated. The migratory 
profiles of the isolates were compared visually and 
analyzed according to the criteria of Tenover et al.27
VRE Surveillance
VRE positive patients were followed up from their 
diagnosis until they had two negative sequential 
swabs and clinical specimens with one week apart 
each other, or until their discharge from the hospital.
In order to prevent further spread of VRE, the ICS 
of our hospital established specific contact control 
measures according to the Guideline for Isolation 
Precautions in Hospitals, 1995, of the United States 
Centers for Diseases Control28. These precautions 
have been maintained from May 2000 to May 2009 
and included active surveillance with weekly rectal 
swabs of GICU patients and control of all clinical 
materials from any unit of the hospital with identified 
cases of VRE. Positive patients, colonized and/or 
infected with VRE were subjected to weekly swabs 
and collection of clinical material; they were taken 
from the isolation when two subsequent swabs and 
clinical specimens were negative for VRE.
Once a patient was identified as being infected 
or colonized with VRE, he/she was put in a private 
room or in shared rooms with other VRE positive 
patients and advised not to visit common areas on 
the ward. Educational sessions were provided to all 
healthcare workers reinforcing contact precautions 
including hand hygiene, use of gloves and gowns, 
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individualized equipments for each room (thermometers, 
stethoscopes, sphygmomanometers); in addition, if 
the patient traveled to another part of the hospital, 
he/she must be conducted in wheel chairs by the 
health team appropriately worn with gown and glove. 
Environmental cleaning procedures included daily 
cleaning of patient rooms and “terminal cleaning” 
at patient discharge. A sodium hypochlorite-based 
disinfectant was used for cleaning (Virex). The correct 
use of vancomycin was emphasized.
Only one hospitalization and one positive culture 
(the first to appear) per patient were considered.
Statistical Analysis
The statistical analyses were performed using 
SPSS, version 10.0. Results from descriptive statistics 
were presented in tables and graphics.
RESULTS
From May 2000 to April 2009, 315 cases of VRE 
were identified, of which 224 were isolated from rectal 
swabs and 91 from other clinical samples, mainly 
blood, followed by urine (table 1).
Strains of vancomycin resistant and ampicilin 
susceptible Enterococcus faecalis were identified in 
312 isolates, of vancomycin and ampicilin resistant 
E. faecalis in 2 isolates, and of vancomycin and 
ampicilin resistant Enterococcus faecium in 1 isolate. 
Molecular typing was done in 47 VRE isolates, 37 of 
which were from a rectal swab, 5 from secretion, 4 from 
blood, and 1 from urine. A well-defined DNA migratory 
profile could be observed for 46 VRE isolates, as only 
one did not migrate. The comparison of DNA profiles 
indicated that 39 isolates were indistinguishable, as 
there was no visible difference between the bands. 
This profile was designated profile “A”. Four isolates 
presented migratory profiles closely related to profile 
“A”, differing from it in only two bands (genotype A1, 
three isolates) and in three bands (genotype A2, one 
isolate). Three other isolates presented migratory 
profiles that were different from profile “A” by more 
than seven bands and were designated profiles 
“B”, “C” and “D”. The discriminatory power of PFGE 
was evaluated by comparing VRE and VSE isolates 
obtained from the same patients. VSE isolates 
presented totally different migratory profiles when 
compared to clone A.
The annual distribution of new VRE cases showed 
a clear decrease from 2000 to 2009 in Intensive 
Care Units (ICUs) and hospital wards (figure 1).The 
first cases identified at the beginning of 2000 were 
admitted to the GICU, but the outbreak extended to 
five different units: clinical and surgical unit, post-
cardiac surgical ICU, coronary ICU, pediatric ICU 
and post-surgical recovery unit (table 2).
Table 1: VRE distribution according to the materials used 
for bacterial identification.
Material n %
Rectal swab 224 71.11
Blood culture 36 11.43
Urine culture 29 9.21
Others 26 8.25
Total 315 100.00
Figure 1: Distribution of the new VRE cases in the ICUs (straight line) and hospital wards (dotted line) from 2000 to 2009.
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The median time of hospitalization was 46 days 
(1 to 393 days) and the median time of hospitalization 
before VRE was isolated for the first time was 21 days 
(1 to 366 days). People over 60 years were the most 
affected (table 3).
DISCUSSION
This study demonstrates substantial VRE colonization 
(71.1%) in patients admitted to our hospital as assessed 
by rectal swab; among the clinical materials used for 
bacterial identification, blood and urine were the most 
important. The indistinguishable profile observed 
for the vast majority of the VRE isolates in PFGE 
indicates a transversal environmental mode of spread. 
Our results are consistent with earlier studies that 
indicated clonal dissemination as a major mechanism 
for spreading of isolates20-22. However, the absolute 
predominance (99.68% ) of E. faecalis among VRE 
cases during the period of the study is not consistent 
with what has been reported in the literature, which 
largely describes a higher prevalence of vancomycin 
resistant E. faecium29-32. Studies from Porto Alegre, 
Southern Brazil, also demonstrated the important 
occurrence of vancomycin-resistant E. faecium during 
recent years33.The predominance of VRE in older 
people and in ICUs are also observed in literature. 
The incidence distribution curve for VRE in our 
hospital shows that it almost disappeared throughout 
the 9-year period observed. The implementation of 
specific and persistent infection control measures 
probably played a crucial role in these results as we 
can observe in many publications23,24,34-38.
In conclusion, following the VRE pattern across 
a 9-year period allowed us to learn how to deal 
with these resistant bacteria and to understand that 
its presence can be an excellent indication of the 
capacity of the unit to maintain the safety measures to 
avoid the cross transmission of the microorganisms. 
Continuous surveillance of VRE is mandatory due 
to its clinical and epidemiologic importance, in order 
to promptly implement specific control measures to 
prevent new outbreaks.
Table 2: VRE distribution according to the units of 
hospitalization.
Unit n (%)
GICU* 171 54.28
Clinical and surgical unit 113 35.87
Post-cardiac surgical ICU** 5 1.59
Coronary ICU 20 6.35
Pediatric ICU 3 0.95
Post-surgical unit 3 0.95
Total 315 100.00
*GICU= General Intensive Care Unit ; **ICU= Intensive Care Unit.
Table 3: VRE distribution according to patients’ age.
Age n (%)
0 ┤ 19 15 4.8
20 ┤ 39 56 17.8
40 ┤ 59 80 25.4
60 ┤ 164 52.0
Total 315 100.0
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